{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["28(14)"],"submitter":["Marin D"],"pubmed_abstract":["<h4>Purpose</h4>There is a considerable variability in the level of molecular responses achieved with imatinib therapy in patients with chronic myeloid leukemia (CML). These differences could result from variable therapy adherence.<h4>Methods</h4>Eighty-seven patients with chronic-phase CML treated with imatinib 400 mg/d for a median of 59.7 months (range, 25 to 104 months) who had achieved complete cytogenetic response had adherence monitored during a 3-month period by using a microelectronic monitoring device. Adherence was correlated with levels of molecular response. Other factors that could influence outcome were also analyzed.<h4>Results</h4>Median adherence rate was 98% (range, 24% to 104%). Twenty-three patients (26.4%) had adherence <or= 90%; in 12 of these patients (14%), adheren"],"journal":["Journal of clinical oncology : official journal of the American Society of Clinical Oncology"],"pagination":["2381-8"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6366340"],"repository":["biostudies-literature"],"pubmed_title":["Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib."],"pmcid":["PMC6366340"],"pubmed_authors":["Kozlowski K","Mahon FX","Eliasson L","Reid A","Bua M","Latham V","Guallar C","Molimard M","Szydlo R","Desai R","Paliompeis C","Milojkovic D","Khorashad JS","Bazeos A","Foroni L","Goldman J","Apperley JF","Rezvani K","Marin D","de Lavallade H"],"additional_accession":[]},"is_claimable":false,"name":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.","description":"<h4>Purpose</h4>There is a considerable variability in the level of molecular responses achieved with imatinib therapy in patients with chronic myeloid leukemia (CML). These differences could result from variable therapy adherence.<h4>Methods</h4>Eighty-seven patients with chronic-phase CML treated with imatinib 400 mg/d for a median of 59.7 months (range, 25 to 104 months) who had achieved complete cytogenetic response had adherence monitored during a 3-month period by using a microelectronic monitoring device. Adherence was correlated with levels of molecular response. Other factors that could influence outcome were also analyzed.<h4>Results</h4>Median adherence rate was 98% (range, 24% to 104%). Twenty-three patients (26.4%) had adherence <or= 90%; in 12 of these patients (14%), adheren","dates":{"release":"2010-01-01T00:00:00Z","publication":"2010 May","modification":"2025-06-01T12:39:51.136Z","creation":"2025-06-01T12:39:51.136Z"},"accession":"S-EPMC6366340","cross_references":{"pubmed":["20385986"],"doi":["10.1200/jco.2009.26.3087","10.1200/JCO.2009.26.3087"]}}